Filtered By:
Vaccination: Veterinary Vaccinations
This page shows you your search results in order of date. This is page number 16.
Order by Relevance | Date
Total 406 results found since Jan 2013.
Evaluating the Immune Response of Recombinant H1N1 Hemagglutinin with MF59 Adjuvant in Animal Model as a Novel Alternative to the Influenza Vaccine
This study examines the potential function of formulated H1N1 hemagglutinin with MF59 adjuvant against A/PR/8/34 (H1N1). To this end, a recombinant hemagglutinin (rHA) gene of influenza A virus was designed and expressed in SF9 cell by the Baculovirus expression system. Four groups of mice were immunized by rHA in combination with MF59, Alum adjuvant, and virus split only. The immunized mice subsequently used for the humoral immune assay and the results compared with untreated mice (negative group). Besides, both treated and control mice groups were challenged with mouse-adapted influenza virus A/PR/8/34(H1N1) through the ...
Source: Iranian Journal of Allergy, Asthma and Immunology - January 19, 2021 Category: Allergy & Immunology Authors: Niloufar Rashedi Morteza Taghizadeh Parisa Mohamadynejad Mehdi Mahdavi Reza Jalalirad Source Type: research
The COVID-19 Virus Is Mutating. What Does That Mean for Vaccines?
As we enter the second year of living with the new coronavirus SARS-CoV-2, the virus is celebrating its invasion of the world’s population with yet more mutated forms that help it to spread more easily from person to person.
One, first detected in the U.K. in December, has already raised alarms about whether the COVID-19 virus is now escaping from the protection that vaccines just being rolled out now might provide. The variant has also been found in the U.S. Already, U.K. officials have tightened lockdowns in England, Scotland and Wales, and over the holidays, more than 40 countries banned travelers from the region ...
Source: TIME: Health - January 7, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
Toll-like receptors (TLRs) are essential components of innate immunity and provide defensive inflammatory responses to invading pathogens. Located within the plasma membranes of cells and also intracellular endosomes, TLRs can detect a range of pathogen associated molecular patterns from bacteria, viruses and fungi. TLR activation on dendritic cells can propagate to an adaptive immune response, making them attractive targets for the development of both prophylactic and therapeutic vaccines. In contrast to conventional adjuvants such as aluminium salts, TLR agonists have a clear immunomodulatory profile that favours anti-al...
Source: Frontiers in Immunology - November 12, 2020 Category: Allergy & Immunology Source Type: research
FDA Issues Recommendations for Certain High-Risk Groups Regarding Mercury-Containing Dental Amalgam
For Immediate Release:September 24, 2020Statement From:Director - CDRH Offices: Office of the Center DirectorDr. Jeffrey E. Shuren MD, JDPart of our role in protecting patients is to regularly evaluate, monitor and update scientific evidence on the risks from medical devices —including issues related to the materials used in devices, such as metals. In the case of implanted and inserted medical devices, where materials may be in contact with the body for extended periods of time, we evaluate safety issues involved with, among other things, the body’s long-term expos ure to certain materials, taking into account t...
Source: Dental Technology Blog - November 11, 2020 Category: Dentistry Source Type: news
The Covid Pandemic: Broadening the Discourse
Thailand’s COVID-19 response an example of resilience and solidarity: a UN Resident Coordinator’s BlogBy Asoka BandarageCOLOMBO, Sri Lanka, Nov 10 2020 (IPS) SARS-CoV-2, the corona virus that causes COVID-19, has been spreading exponentially across the world over the last ten or so months. As of November 6th, according to the Center for Systems Science at Johns Hopkins University, there have been 49,195,581 cases of COVID-19, including 1,241,031 deaths.
More than a third of the global population has been placed on lockdown. The global economy is experiencing the deepest global recession since World War 2 and massive n...
Source: IPS Inter Press Service - Health - November 10, 2020 Category: International Medicine & Public Health Authors: Asoka Bandarage Tags: Featured Global Headlines Health Human Rights Humanitarian Emergencies Peace TerraViva United Nations Source Type: news
Evaluating the Immune Response of Recombinant H1N1 Hemagglutinin with MF59 Adjuvant in Animal Model as a Novel Alternative to the Influenza Vaccine.
This study examines the potential function of formulated H1N1 hemagglutinin with MF59 adjuvant against A/PR/8/34 (H1N1). To this end, a recombinant hemagglutinin (rHA) gene of influenza A virus was designed and expressed in SF9 cell by the Baculovirus expression system. Four groups of mice were immunized by rHA in combination with MF59, Alum adjuvant, and virus split only. The immunized mice subsequently used for the humoral immune assay and the results compared with untreated mice (negative group). Besides, both treated and control mice groups were challenged with mouse-adapted influenza virus A/PR/8/34(H1N1) through the ...
Source: Iranian Journal of Allergy, Asthma and Immunology - October 18, 2020 Category: Allergy & Immunology Authors: Rashedi N, Taghizadeh M, Mohamadynejad P, Mahdavi M, Jalalirad R Tags: Iran J Allergy Asthma Immunol Source Type: research
The Great Vaccine Race: Inside the Unprecedented Scramble to Immunize the World Against COVID-19
The cleverest of enemies thrive on surprise attacks. Viruses—and coronaviruses in particular—know this well. Remaining hidden in animal hosts for decades, they mutate steadily, sometimes serendipitously morphing into more effective and efficient infectious agents. When a strain with just the right combination of genetic codes that spell trouble for people makes the leap from animal to human, the ambush begins.
Such was the case with SARS-CoV-2, the coronavirus behind COVID-19, and the attack was mostly silent and insidious at first. Many people infected with SARS-CoV-2 remained oblivious as they served as the v...
Source: TIME: Health - September 10, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Magazine Source Type: news
Moderna Coronavirus Vaccine Test in Monkeys Shows Promise
This coronavirus vaccine developed by government researchers and Moderna enabled the animals to quickly clear the infection from their lungs.
Source: NYT Health - July 29, 2020 Category: Consumer Health News Authors: Denise Grady Tags: Vaccination and Immunization Moderna Inc Clinical Trials Tests (Medical) Research Monkeys and Apes National Institute of Allergy and Infectious Diseases New England Journal of Medicine Vaccine (Journal) your-feed-healthcare Coronavirus Source Type: news
Monoclonal Antibodies that Neutralize B. anthracis Protective Antigen (PA), Lethal Factor (LF) and Edema Factor (EF)
Anthrax, whether resulting from natural or bioterrorist-associated exposure, is a constant threat to human health. The lethality of anthrax is primarily the result of the effects of anthrax toxin, which has 3 components: a receptor-binding protein known as " protective antigen " (PA) and 2 catalytic proteins known as " lethal factor " (LF) and " edema factor " (EF). Although production of an efficient anthrax vaccine is an ultimate goal, the benefits of vaccination can be expected only if a large proportion of the population at risk is immunized. The low incidence of anthrax suggests that large-scale vaccination may not be...
Source: NIH OTT Licensing Opportunities - July 9, 2020 Category: Research Authors: ott-admin Source Type: research
Protein Nanoparticles for Antigen Display in Vaccines
The technology relates to a protein-based nanoparticle platform that allows presentation of immunogenic molecules such as influenza virus antigens. This protein platform is made up of hepatitis B capsid/core proteins. The core proteins contain immunogenic loop c/e1, where other antigens can be inserted and the chimeric protein retains the ability to form capsid-like particles. The technology describes the insertion of one or more copies of influenza epitopes derived from the globular head or the stem region of hemagglutinin protein into or around the c/e1 loop of the core protein. The nanoparticles formed by the use of Hep...
Source: NIH OTT Licensing Opportunities - July 6, 2020 Category: Research Authors: ott-admin Source Type: research
Coronavirus Vaccine: Here Are The Latest Developments
(CNN) — While coronavirus keeps spreading and killing with impunity, the world waits for a vaccine that could quash the pandemic.
But details and timelines keep shifting. Here’s the latest on where we stand in the race for a vaccine:
When will a Covid-19 vaccine be available to the public?
No one’s sure yet, but the target is sometime in early 2021.
Vaccines in development around the world are in various stages of testing. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said he’s confident one of the vaccine candidates will be proven safe and effective by th...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 8, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Closures Covid-19 Boston, MA Health Healthcare Status Coronavirus Coronavirus Vaccine Moderna Therapeutics Source Type: news
Johnson & Johnson Receives Positive CHMP Opinion for Janssen ’s Investigational Preventive Ebola Vaccine Regimen
Discussions with the FDA are ongoing to define the required data set for filing Janssen’s Ebola vaccine regimen under the FDA’s Animal Rule licensure pathway. About Janssen’s Ebola Vaccine Regimen The Janssen investigational preventive Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo) utilizes a viral vector strategy in which viruses – in this case adenovirus serotype 26 (Ad26) and Modified Vaccinia Virus Ankara (MVA) – are genetically modified so that they cannot replicate in human cells. In addition, these vectors are modified to safely carry the genetic code of an Ebola virus protein in order to trigger an immun...
Source: Johnson and Johnson - May 29, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
